TSC2
TSC2 (tuberin) is the catalytic GAP subunit of the TSC1-TSC2 complex that inhibits Rheb and thereby mTORC1. As a direct substrate of both AKT (inactivating) and AMPK (activating), it is the integration point between growth and energy-sensing pathways.
Key Takeaways
- •TSC2 (Tuberin) is the catalytic "engine" of the complex that keeps mTORC1 switched off.
- •It integrates opposing signals: Insulin turns it OFF (via Akt), while low energy turns it ON (via AMPK).
- •Loss of TSC2 function is the primary driver of Tuberous Sclerosis Complex and LAM.
- •Rapamycin treats TSC2-deficient diseases by blocking the downstream mTOR target.
Basic Information
- Gene Symbol
- TSC2
- Full Name
- Tuberous Sclerosis Complex 2
- Also Known As
- Tuberin
- Location
- 16p13.3
- Protein Type
- GTPase Activating Protein (GAP)
- Protein Family
- TSC Complex (with TSC1)
Related Isoforms
Key SNPs
Located near the TSC1/TSC2 locus; eQTL studies suggest potential effects on gene expression levels.
Synonymous variant; often serves as a marker in linkage disequilibrium with other functional variations.
Over 2,000 unique pathogenic mutations identified; associated with Tuberous Sclerosis Complex and LAM.
Acquired loss-of-function mutations drive sporadic Lymphangioleiomyomatosis (LAM) and some cancers.
Overview
TSC2 (Tuberin) acts as the central processor for the cell's growth decisions. It is the catalytic half of the TSC complex (partnered with TSC1) and possesses the enzymatic ability to turn off Rheb, the direct activator of mTORC1. By keeping Rheb in an inactive state, TSC2 ensures that cells do not grow when nutrients are scarce or stress is high.
What makes TSC2 unique is its sensitivity to phosphorylation. It is covered in "switches" targeted by other kinases. Insulin signaling (via Akt) flips switches that turn TSC2 off, allowing growth. Energy stress (via AMPK) flips switches that turn TSC2 on, halting growth. This makes TSC2 the physical intersection of the insulin and energy pathways.
Conceptual Model
A simplified mental model for the pathway:
If TSC2 is broken (mutation), the brake line is cut. No matter how hard AMPK presses (diet/exercise), the car won't stop accelerating (tumor growth).
Core Health Impacts
- • Tumor Suppression: Prevents benign and malignant overgrowth in multiple organ systems.
- • Metabolic Flexibility: Switches metabolism from anabolic (storage) to catabolic (burning) modes during fasting.
- • Brain Function: Critical for neuronal migration and synaptic pruning; dysfunction leads to epilepsy and autism.
- • Cell Size Control: Regulates cell volume; TSC2-deficient cells become pathologically large ("giant cells").
Protein Domains
GAP Domain
The business end. Interacts with Rheb to stimulate GTP hydrolysis. This is the domain that directly inhibits mTORC1.
TSC1 Binding Domain
Located at the N-terminus. Binding to TSC1 prevents TSC2 from being ubiquitinated and degraded.
Phospho-Motifs
Specific sequences recognized by Akt (RxRxxS/T) and AMPK. These determine the functional state and localization of the protein.
Upstream Regulators
AMPK Activator
The energy sensor. Phosphorylates TSC2 at Ser1387 to enhance its GAP activity, ensuring mTOR stays off during energy stress.
GSK3β Activator
Phosphorylates TSC2 (primed by AMPK) to bolster its stability and activity, integrating Wnt signaling inputs.
REDD1 Activator
Hypoxia-induced factor that scavenges 14-3-3 proteins, preventing them from inhibiting TSC2, thus suppressing mTOR in low oxygen.
p53 Activator
Genome guardian. Induces Sestrin1/2 to activate AMPK-TSC2, pausing growth to prevent replication of damaged DNA.
Downstream Targets
Rheb Inhibits
Ras Homolog Enriched in Brain. TSC2 stimulates Rheb to hydrolyze GTP into GDP, turning it "Off". This is the primary function of TSC2.
mTORC1 Inhibits
Mechanistic Target of Rapamycin Complex 1. Directly activated by Rheb-GTP; therefore, TSC2 directly suppresses mTORC1.
TFEB Activates
Transcription factor for lysosomal biogenesis. By inhibiting mTORC1, TSC2 indirectly promotes TFEB nuclear translocation.
HIF-1α Inhibits
Hypoxia Inducible Factor. Regulated translationally by mTORC1; TSC2 loss leads to high HIF-1α and angiogenesis.
Role in Aging
TSC2 is a pro-longevity factor. By suppressing mTORC1, it lowers the "rate of living," reduces the accumulation of cellular garbage (via autophagy), and improves metabolic health. Interventions that extend lifespan (CR, Rapamycin) largely work by mimicking or restoring TSC2 function.
Autophagy Induction
Active TSC2 allows ULK1 to initiate autophagy, cleaning out damaged mitochondria and protein aggregates that drive aging.
Proteostasis
By slowing down protein synthesis (via mTOR inhibition), TSC2 prevents the ribosome from being overwhelmed, reducing protein misfolding errors.
Stem Cell Exhaustion
Hyperactive mTOR (low TSC2) forces stem cells to divide and differentiate prematurely, depleting the body's regenerative capacity.
Disorders & Diseases
Tuberous Sclerosis Complex
Germline mutations in TSC2 (or TSC1). Causes benign tumors in brain, kidneys, heart, lungs, and skin. TSC2 mutations often result in a more severe phenotype than TSC1 mutations.
Lymphangioleiomyomatosis (LAM)
A destructive lung disease in women driven by somatic TSC2 mutations. Smooth muscle cells proliferate in the lungs, creating cysts and risk of collapse (pneumothorax).
Sporadic Cancers
Loss of TSC2 or TSC1 is observed in bladder cancer, renal cell carcinoma, and rare sarcomas (PEComas), leading to constitutive mTOR activation.
Neurodevelopmental Disorders
High rates of autism spectrum disorder (ASD) and intellectual disability in TSC patients due to disrupted synaptic plasticity and cortical organization.
Interventions
Supplements
Activates AMPK, which phosphorylates TSC2 to suppress mTOR. Mimics energy stress signaling.
activates AMPK, reinforcing the TSC2 "brake" on cell growth and metabolism.
Polyphenol that may support AMPK pathway activity, indirectly favoring TSC2 function.
Flavonoid reported to influence PI3K/Akt pathways, potentially reducing the inhibitory signal on TSC2.
Lifestyle
Reduces insulin (releasing the Akt brake on TSC2) and increases AMPK (stepping on the TSC2 brake).
Lowers amino acid availability and IGF-1, reducing the pressure to inactivate TSC2.
Acutely depletes cellular ATP, triggering AMPK to phosphorylate and activate TSC2 in muscle tissue.
Medicines
Bypasses TSC2 entirely to inhibit mTORC1 directly. The standard of care for TSC2-deficient tumors.
A rapalog used clinically for SEGA (brain tumors) and renal angiomyolipomas associated with TSC.
Investigational. By blocking Akt, they prevent the inhibitory phosphorylation of TSC2, restoring its function.
Lab Tests & Biomarkers
Genetic Testing
Checks for germline mutations. Because TSC2 is large (41 exons), next-gen sequencing is standard.
Clinical Monitoring
Monitoring for angiomyolipomas is critical, as they can bleed if they grow too large.
For women with TSC or sporadic LAM, tracking lung function (FEV1) detects progression.
Hormonal Interactions
Insulin Inhibitor
Triggers Akt to phosphorylate TSC2 at Ser939/Thr1462, causing it to detach from the lysosome (Growth ON).
IGF-1 Inhibitor
Potent growth factor that inactivates TSC2 via the PI3K-Akt axis to drive anabolic processes.
Glucagon Activator
Opposes insulin; signals via cAMP/PKA to potentially stabilize TSC2 function in the liver.
Cortisol Context-Dependent
Chronic stress/glucocorticoids can induce insulin resistance, altering the baseline TSC2 phosphorylation state.
Deep Dive
Network Diagrams
TSC2 Phosphorylation Switch
Lysosomal Localization Cycle
Mechanism: The Phosphorylation Code
TSC2 is regulated almost entirely by phosphorylation, acting as a logical “AND/OR” gate. The protein has distinct sites for different inputs:
- Akt sites (Ser939, Thr1462): Phosphorylation here creates binding pockets for 14-3-3 proteins. 14-3-3 binding physically pulls TSC2 away from the lysosomal membrane (where Rheb lives), effectively “sequestering” the brake. Result: Brake OFF.
- AMPK site (Ser1387): Phosphorylation here enhances the GAP activity of TSC2 and promotes its association with TSC1. It overrides the Akt signal if energy is truly low. Result: Brake ON.
- ERK/RSK sites (Ser664, Ser1798): Mitogenic signals (cell division cues) also phosphorylate TSC2 to inhibit it, ensuring mTOR is active during cell division.
Location, Location, Location
Biology is spatial. The target of TSC2, Rheb, is anchored to the surface of the lysosome. Therefore, for TSC2 to work, it must be at the lysosome.
When insulin spikes, Akt phosphorylates TSC2, causing it to drift away into the cytoplasm (bound to 14-3-3). The lysosomal surface is left unguarded, allowing Rheb to accumulate GTP and activate mTOR. When insulin drops, phosphatases remove the tags, and TSC2 returns to the lysosome to re-assert control.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
The discovery of the TSC2 gene and its link to Tuberous Sclerosis Complex.
Established the TSC1-TSC2 complex as the critical negative regulator of mTOR signaling.
Identified AMPK phosphorylation of TSC2 as the mechanism linking energy status to cell growth.
Solved the puzzle of "how" TSC2 inhibits mTOR: by acting as a GAP for the small GTPase Rheb.
Mechanistic detail on how insulin/Akt signaling physically sequesters TSC2 away from its target.
Review of LAM, a disease caused by somatic TSC2 mutations and commonly treated with mTOR inhibitors.